Storia in 3 fonti

Unicycive gets second CRL for kidney drug as manufacturing woes continue

Unicycive's CKD drug oxylanthanum carbonate gets a second FDA rejection over third-party manufacturing issues; shares drop ~50% premarket.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Unicycive's CKD drug oxylanthanum carbonate gets a second FDA rejection over third-party manufacturing issues; shares drop ~50% premarket.

Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again over third-party manufacturing issues.